Mechanism of Class Switch Recombination
类切换重组机制
基本信息
- 批准号:8891660
- 负责人:
- 金额:$ 34.04万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2009
- 资助国家:美国
- 起止时间:2009-04-01 至 2016-07-31
- 项目状态:已结题
- 来源:
- 关键词:AddressAntibodiesB-Cell NeoplasmBiologyCellsChromosomal translocationCytosineDNADNA LigasesDNA lesionDeaminationElementsEnhancersEventFrequenciesGene ConversionGenetic RecombinationGenetic TranscriptionGenomeGenomicsHealthHematopoietic NeoplasmsImmune System DiseasesImmune systemImmunoglobulin Class SwitchingImmunoglobulin GenesImmunoglobulin Somatic HypermutationImmunoglobulin Switch RecombinationInfectionKnowledgeLesionMediatingMutationOncogenicPathologyPositioning AttributeProductionReactionTranscriptional RegulationUracilactivation-induced cytidine deaminasein vivopromoter
项目摘要
DESCRIPTION (provided by applicant): Activation-induced cytidine deaminase (AID) initiates immunoglobulin gene somatic hypermutation, gene conversion and class switch recombination (CSR) by inflicting DNA lesions at specific genomic loci via DNA cytosine deamination (that converts cytosine to uracil). While these lesions are essential for the production of optimized antibodies against infections, they are also threats to the genome integrity. AID-associated oncogenic mutations and chromosomal translocations are frequently seen in tumors of B cell origin. We propose three specific aims to address several significant gaps in our knowledge about the mechanism of CSR. In aim 1, we will manipulate the transcription control elements (promoters/enhancers) at IgH α locus in CH12F3 cells to identify cis-acting DNA elements critical for targeting AID to switch (S) regions. In aim 2, we will determine the frequency and precise positions of AID footprints in S regions to delineate AID actions in vivo during CSR. In aim 3, we will determine which DNA ligase is responsible for alternative end-joining of S region breaks.
描述(申请人提供):激活诱导型胞苷脱氨酶(AID)通过DNA胞嘧啶脱氨作用(将胞嘧啶转化为尿嘧啶)在特定的基因组座位上造成DNA损伤,从而启动免疫球蛋白基因的体细胞超突变、基因转换和类别切换重组(CSR)。虽然这些损伤对于产生优化的抗感染抗体是必不可少的,但它们也是对基因组完整性的威胁。与艾滋病相关的致癌突变和染色体易位常见于B细胞起源的肿瘤。我们提出了三个具体目标,以解决我们对企业社会责任机制认识上的几个重大差距。在目标1中,我们将操纵CH12F3细胞中IgHα基因座的转录调控元件(启动子/增强子),以确定与靶向艾滋病转开关(S)区域至关重要的顺式作用元件。在目标2中,我们将确定艾滋病足迹在S区域的频率和精确位置,以描绘艾滋病在CSR期间在体内的作用。在目标3中,我们将确定哪个DNA连接酶负责S区域断裂的选择性末端连接。
项目成果
期刊论文数量(1)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
The SAGA Deubiquitination Module Promotes DNA Repair and Class Switch Recombination through ATM and DNAPK-Mediated γH2AX Formation.
- DOI:10.1016/j.celrep.2016.04.041
- 发表时间:2016-05-17
- 期刊:
- 影响因子:8.8
- 作者:Ramachandran S;Haddad D;Li C;Le MX;Ling AK;So CC;Nepal RM;Gommerman JL;Yu K;Ketela T;Moffat J;Martin A
- 通讯作者:Martin A
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Kefei Yu其他文献
Kefei Yu的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Kefei Yu', 18)}}的其他基金
DNA Structure Directed AID Deamination During Immunoglobulin Isotype Switching
免疫球蛋白同种型转换过程中 DNA 结构定向 AID 脱氨基作用
- 批准号:
9573844 - 财政年份:2018
- 资助金额:
$ 34.04万 - 项目类别:
DNA Structure Directed AID Deamination During Immunoglobulin Isotype Switching
免疫球蛋白同种型转换过程中 DNA 结构定向 AID 脱氨基作用
- 批准号:
9750168 - 财政年份:2018
- 资助金额:
$ 34.04万 - 项目类别:
Targeted DNA cleavage at switch regions in immunoglobulin class switch recombinat
免疫球蛋白类别转换重组中转换区域的靶向 DNA 切割
- 批准号:
8507595 - 财政年份:2009
- 资助金额:
$ 34.04万 - 项目类别:
Targeted DNA cleavage at switch regions in immunoglobulin class switch recombinat
免疫球蛋白类别转换重组中转换区域的靶向 DNA 切割
- 批准号:
8113245 - 财政年份:2009
- 资助金额:
$ 34.04万 - 项目类别:
Targeted DNA cleavage at switch regions in immunoglobulin class switch recombinat
免疫球蛋白类别转换重组中转换区域的靶向 DNA 切割
- 批准号:
8306980 - 财政年份:2009
- 资助金额:
$ 34.04万 - 项目类别:
Targeted DNA cleavage at switch regions in immunoglobulin class switch recombinat
免疫球蛋白类别转换重组中转换区域的靶向 DNA 切割
- 批准号:
7739820 - 财政年份:2009
- 资助金额:
$ 34.04万 - 项目类别:
Targeted DNA cleavage at switch regions in immunoglobulin class switch recombinat
免疫球蛋白类别转换重组中转换区域的靶向 DNA 切割
- 批准号:
7907764 - 财政年份:2009
- 资助金额:
$ 34.04万 - 项目类别:
相似海外基金
University of Aberdeen and Vertebrate Antibodies Limited KTP 23_24 R1
阿伯丁大学和脊椎动物抗体有限公司 KTP 23_24 R1
- 批准号:
10073243 - 财政年份:2024
- 资助金额:
$ 34.04万 - 项目类别:
Knowledge Transfer Partnership
Role of Natural Antibodies and B1 cells in Fibroproliferative Lung Disease
天然抗体和 B1 细胞在纤维增生性肺病中的作用
- 批准号:
10752129 - 财政年份:2024
- 资助金额:
$ 34.04万 - 项目类别:
CAREER: Next-generation protease inhibitor discovery with chemically diversified antibodies
职业:利用化学多样化的抗体发现下一代蛋白酶抑制剂
- 批准号:
2339201 - 财政年份:2024
- 资助金额:
$ 34.04万 - 项目类别:
Continuing Grant
Isolation and characterisation of monoclonal antibodies for the treatment or prevention of antibiotic resistant Acinetobacter baumannii infections
用于治疗或预防抗生素耐药鲍曼不动杆菌感染的单克隆抗体的分离和表征
- 批准号:
MR/Y008693/1 - 财政年份:2024
- 资助金额:
$ 34.04万 - 项目类别:
Research Grant
Discovery of novel nodal antibodies in the central nervous system demyelinating diseases and elucidation of the mechanisms through an optic nerve demyelination model
发现中枢神经系统脱髓鞘疾病中的新型节点抗体并通过视神经脱髓鞘模型阐明其机制
- 批准号:
23K14783 - 财政年份:2023
- 资助金额:
$ 34.04万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Elucidation of the mechanisms controlling the physicochemical properties and functions of supercharged antibodies and development of their applications
阐明控制超电荷抗体的理化性质和功能的机制及其应用开发
- 批准号:
23KJ0394 - 财政年份:2023
- 资助金额:
$ 34.04万 - 项目类别:
Grant-in-Aid for JSPS Fellows
Developing first-in-class aggregation-specific antibodies for a severe genetic neurological disease
开发针对严重遗传神经系统疾病的一流聚集特异性抗体
- 批准号:
10076445 - 财政年份:2023
- 资助金额:
$ 34.04万 - 项目类别:
Grant for R&D
PLA2G2D Antibodies for Cancer Immunotherapy
用于癌症免疫治疗的 PLA2G2D 抗体
- 批准号:
10699504 - 财政年份:2023
- 资助金额:
$ 34.04万 - 项目类别:
Genetic adjuvants to elicit neutralizing antibodies against HIV
基因佐剂可引发抗艾滋病毒中和抗体
- 批准号:
10491642 - 财政年份:2023
- 资助金额:
$ 34.04万 - 项目类别:
Novel Immunogens to Elicit Broadly Cross-reactive Antibodies That Target the Hemagglutinin Head Trimer Interface
新型免疫原可引发针对血凝素头三聚体界面的广泛交叉反应抗体
- 批准号:
10782567 - 财政年份:2023
- 资助金额:
$ 34.04万 - 项目类别:














{{item.name}}会员




